The Full Wiki

Hyperprolactinaemia: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Classification and external resources

ICD-10 E22.1
ICD-9 253.1
DiseasesDB 6314
eMedicine med/1098
MeSH D006966

Hyperprolactinaemia (HP), or hyperprolactinemia in the United States (U.S.), is the presence of abnormally-high levels of prolactin in the blood. Normal levels are less than 580 mIU/L for women, and less than 450 mIU/L for men.

Prolactin is a peptide hormone produced by the anterior pituitary gland primarily associated with lactation and plays a vital role in breast development during pregnancy. Hyperprolactinaemia may cause production and spontaneous flow of breast milk and disruptions in the normal menstrual period in women and hypogonadism, infertility and erectile dysfunction in men.

Hyperprolactinaemia can be a part of normal body changes during pregnancy and breastfeeding. It can also be caused by diseases affecting the hypothalamus and pituitary gland. It can also be caused by disruption of the normal regulation of prolactin levels by drugs, medicinal herbs and heavy metals. Hyperprolactinaemia may also be the result of disease of other organs such as the liver, kidneys, ovaries and thyroid.[1]



Hyperprolactinaemia may be caused by either disinhibition (e.g., compression of the pituitary stalk or reduced dopamine levels) or excess production from a prolactinoma (a pituitary gland adenoma tumour). A blood serum prolactin level of 1000–5000 mIU/L could be from either mechanism, but >5000 mIU/L is likely due to the activity of an adenoma with macroadenomas (large tumours over 10 mm diameter) whose levels of prolactin are up to 100,000 mIU/L. Hyperprolactinemia inhibits gonadotropin-releasing hormone (GnRH) by increasing the release of dopamine from the arcuate nucleus of the hypothalamus (dopamine inhibits GnRH secretion), thus inhibiting gonadal steroidogenesis, which is the cause of many of the symptoms described below.

There is a suspicion that Minoxidil, a potassium channel agonist, may be related to the development of this disease. A two-year test with Minoxidil, under normal dosing parameters, was carried out on rats, which caused pheochromocytomas in both males and females, and preputial gland adenomas in males[2].

Physiological causes

Physiological causes (i.e., as result of normal body functioning): pregnancy, breastfeeding, stress, sleep, hypothyroidism.

Prescription drugs

Use of prescription drugs is the most common cause of hyperprolactinaemia. Prolactin secretion in the pituitary is normally suppressed by the brain chemical dopamine. Drugs that block the effects of dopamine at the pituitary or deplete dopamine stores in the brain may cause the pituitary to secrete prolactin. These drugs include the major tranquilizers (phenothiazines), trifluoperazine (Stelazine), and haloperidol (Haldol); antipsychotic medications in general; metoclopramide (Reglan), domperidone, cisapride used to treat gastroesophageal reflux and medication induced nausea(such as cancer drugs); and, less often, alpha-methyldopa and reserpine, used to control hypertension; and oestrogens and TRH. The sleep drug ramelteon (Rozerem) also increases the risk of hyperprolactinemia. In particular, the dopamine antagonists metoclopramide and domperidone are both powerful prolactin stimulators and have been used to stimulate breastmilk secretion for decades. However since prolactin is antagonized by dopamine and the body depends on the two being in balance, the risk of prolactin stimulation is generally present with all drugs that deplete dopamine, either directly or as a rebound effect.


Prolactinoma or other tumors arising in or near the pituitary — such as those that cause acromegaly or Cushing's syndrome — may block the flow of dopamine from the brain to the prolactin-secreting cells, likewise, division of the pituitary stalk or hypothalamic disease. Other causes include chronic renal failure, hypothyroidism, and sarcoidosis. Some women with polycystic ovary syndrome may have mildly-elevated prolactin levels.

Apart from diagnosing hyperprolactinaemia and hypopituitarism, prolactin levels are often determined by physicians in patients that have suffered a seizure, when there is doubt as to whether this was an epileptic seizure or a non-epileptic seizure. Shortly after epileptic seizures, prolactin levels often rise, whereas they are normal in non-epileptic seizures.


In many patients, elevated levels remain unexplained and may represent a form of hypothalamic-pituitary dysregulation.


In women, a high blood level of prolactin often causes hypoestrogenism with anovulatory infertility and a decrease in menstruation. In some women, menstruation may disappear altogether (amenorrhea). In others, menstruation may become irregular or menstrual flow may change. Women who are not pregnant or nursing may begin producing breast milk. Some women may experience a loss of libido (interest in sex). Intercourse may become painful because of vaginal dryness.

In men, the most common symptoms of hyperprolactinemia are decreased libido, erectile dysfunction, and infertility. Because men have no reliable indicator such as menstruation to signal a problem, many men with hyperprolactinemia being caused by an adenoma may delay going to the doctor until they have headaches or eye problems caused by the enlarged pituitary pressing against nearby optic nerves. They may not recognize a gradual loss of sexual function or libido. Only after treatment do some men realize they had a problem with sexual function.

Because of hypoestrogenism, hyperprolactinaemia can lead to osteoporosis.


A doctor will test for prolactin blood levels in women with unexplained milk secretion (galactorrhea) or irregular menses or infertility, and in men with impaired sexual function and, in rare cases, milk secretion. If prolactin is high, a doctor will test thyroid function and ask first about other conditions and medications known to raise prolactin secretion. While a plain X-ray of the bones surrounding the pituitary may reveal the presence of a large macro-adenoma, the small micro-adenoma will not be apparent. Magnetic resonance imaging (MRI) is the most sensitive test for detecting pituitary tumors and determining their size. MRI scans may be repeated periodically to assess tumor progression and the effects of therapy. Computed Tomography (CT scan) also gives an image of the pituitary, but it is less sensitive than the MRI.

In addition to assessing the size of the pituitary tumor, doctors also look for damage to surrounding tissues, and perform tests to assess whether production of other pituitary hormones is normal. Depending on the size of the tumor, the doctor may request an eye exam with measurement of visual fields.

The hormone prolactin is downregulated by dopamine and is upregulated by estrogen. A falsely-high measurement may occur due to the presence of the biologically-inactive macroprolactin in the serum. This can show up as high prolactin in some types of tests, but is asymptomatic.


Two drugs that have been used are the dopamine agonists cabergoline[3] and bromocriptine.[4][5] A new drug in use is norprolac[6] with the active ingredient quinagolide.

Historical eponyms

The following eponyms were established before prolactin levels could be measured reliably in the clinical setting. On occasion, they are still encountered:

  1. Ahumada-DelCastillo Syndrome, which refers to the association of galactorrhea and amenorrhea
  2. Chiari-Frommel Syndrome, which refers to extended postpartum galactorrhea and amenorrhea
  3. Forbes-Albright Syndrome, which refers to galactorrhea-amenorrhea associated with a pituitary tumor.


  1. ^ Mancini, T. (2008), "Hyperprolactinemia and Prolactinomas", Endocrinology & Metabolism Clinics of North America 37: 67, doi:10.1016/j.ecl.2007.10.013, PMID 18226731  
  2. ^ Minoxidil Official FDA information, side effects and uses
  3. ^ Verhelst J, Abs R, Maiter D, et al. (July 1999). "Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients". J. Clin. Endocrinol. Metab. 84 (7): 2518–22. doi:10.1210/jc.84.7.2518. PMID 10404830.  
  4. ^ Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (October 1994). "A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group". N. Engl. J. Med. 331 (14): 904–9. doi:10.1056/NEJM199410063311403. PMID 7915824.  
  5. ^ Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G (April 2006). "Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women". Nat Clin Pract Endocrinol Metab 2 (4): 200–10. doi:10.1038/ncpendmet0160. PMID 16932285.  
  6. ^ Sarno A, Landi M, Marzullo, et al. (November 2000). "The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas". Clin. Endocrinol. 53 (5): 549–550. PMID 10931080.  

Got something to say? Make a comment.
Your name
Your email address